Cholangiocarcinoma (CCA) is a common carcinoma of the liver, and the majority of patients with CCA have a poor prognosis due to the lack of effective non-surgical therapies in addition to its rapid progression and inoperability at the time of diagnosis. The development of novel non-surgical therapeutics that efficiently target CCA could significantly improve the prognosis for patients presenting with CCA. Here, we describe the iterative production and characterization of a novel peptide, designated COP35 (CCA-binding oligo-peptide #35), which binds selectively to human CCA, identified by bacteriophage biopanning using the intrahepatic cholangiocarcinoma cell line RBE and the normal cholangiocyte cell line MMNK-1. COP35 was found to augment the growth inhibitory effects of 5-FU against RBE cells. Utilizing pull-down assay and liquid chromatography, we identify the clathrin heavy chain (CHC) accompanied by GRP78/BiP as a COP35 binding partner. In summary, we identify COP35 as a possible candidate for peptide-targeted therapies for CCA.
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INTRODUCTION
Cholangiocarcinoma (CCA) is a highly malignant tumor that arises from the ductal epithelium of the biliary tree and is a common secondary carcinoma of the liver [1] .
The incidence and mortality rates of CCA are increasing worldwide [2] . Although tumors originating from the common hepatic or bile duct are readily identifiable owing to obstructive jaundice, tumors originating from the small bile duct do not cause significant biliary obstruction until the tumor itself or metastatic lesions cause obstruction of the common hepatic or bile duct [3] . In terms of treatment, complete surgical resection remains the only effective means to cure patients with CCA owing to the difficulty of early diagnosis and the rapid progression of the disease. The main obstacles to complete resection for CCA are the multiplicity of the lesions, that is, multicentric occurrence, intra-hepatic extension, and distant metastasis. Therefore, establishment of a methodology that could efficiently target CCA could dramatically improve the efficacy of treatments for CCA. Most patients with unresectable disease at clinical presentation have a poor prognosis (5-year survival rates are 0-40% even in resected cases) [2, 4] .
Furthermore, CCA responds poorly to chemotherapy, and radiation therapy and conventional treatments are not adequate for the vast majority of patients with CCA.
Moreover, conventional chemotherapy and radiation therapy have shown no efficacy in extending median survival rates, and although photodynamic therapy combined with stenting has been reported to be effective as a palliative treatment, it is not curative. Thus, the development of novel chemopreventive and adjuvant therapeutic strategies based on 3 exploring select molecular targets could impact significantly upon clinical outcomes.
Several groups' studies have identified potential candidate molecular targeting agents to achieve tumor tropism. The ligands that have been evaluated include antibodies, single-chain fragment variables, and growth factors [5] [6] [7] . More recently, peptide-presenting bacteriophage libraries that enable the selection of peptides that bind to selected cell types or ligands have been utilized [8] . The biopanning technique has been shown to be a powerful tool for identifying specific ligands on target organs and tumors since it enables forced evolution of very high-affinity targeting peptides through rounds of selection of living libraries of peptides presented on the surface of the bacteriophage particle [9] [10] [11] [12] . This technique has classically been used to iteratively produce peptides binding purified cell-surface markers [13, 14] , cultured cell lines [15, 16] , or tumor-bearing animals [17] [18] [19] . We utilized a peptide-presenting bacteriophage library based on a combinatorial library of random peptide 12-mers fused to a minor coat protein pIII of the M13-bacteriophage containing approximately 2.7 × 10 9 different sequences, and different peptides selective for the target cells were identified with successive rounds of biopanning. We identified a new oligo-peptide (designated COP35) that specifically bound to CCA cells and its target molecules. We characterized the effects of the selected peptide on tumor inhibition in combination with anticancer agents and elucidated a potential binding partner for COP35. The biopanning procedure was performed as described previously [12] . Briefly, we utilized the M13-phage display 12-peptide library constructed using Phage Display Peptide Library Kit (New England Biolabs, Ipswich, MA). MMNK-1 cells were used as absorber cells for whole-cell subtractive screening, and RBE cells were used as the target cells. Biopanning was performed for a total of three rounds for enrichment of peptides binding selectively and efficiently to CCA. Phage display, isolation, and sequencing of phage DNA were performed as described previously [10, 11] .
MATERIALS AND METHODS
on
Peptide preparation
Custom peptides COP35 "TPVLETPKLLLW", a control peptide "HAKSPEMCTFVG", which has almost the same net hydrophobic/hydrophilic and charge properties as COP35, and trans-acting activator of transcription (TAT) peptide "GRKKRRQRRRPPQ" were purchased from SIGMA Lifescience Custom Peptide Service (SIGMA Genosys, Hokkaido, Japan). Synthetic peptides were HPLC-purified (>95%) with N-terminal biotinylation or N-hydroxy-succinimidyl (NHS)-fluorescein conjugation.
Evaluation of phage clones for their ability to bind to human cancer cells
The evaluation of binding activity of selected phage clones to human cell lines was performed as described previously [11] . RBE cells were cultured and plated into 96-well plates (1 × 10 4 cells/well) the day before use. The cells were washed and fixed in 6 4% paraformaldehyde in PBS for 20 minutes. 1 × 10 10 pfu per well of each selected phage clone was added to the cells at 4°C, unbounded phage were removed by washing cells with PBS, and bound phage were detected by cell-based enzyme-linked immunosorbent assay (ELISA).
Fluorescence microscopy of living cells with synthesized NHS-fluorescein-labeled peptides
Cells were cultured overnight in eight-well chamber slides, and were washed three times with PBS containing 10% FBS. The cells were then incubated with 1.7 mg/ml NHS-fluorescein-labeled peptide (Sigma Genosys, Hokkaido, Japan) for 2 hours at 37°C.
After 2 hours, the medium was discarded and the cells were washed again with PBS containing 10% FBS, and then stained with medium containing 4',6-diamidino-2-phenylindole (DAPI) for nuclear counterstaining (Invitrogen, Grand
Island, NY), and the samples were imaged using a fluorescence microscope. 
Evaluation of cell growth
To gauge toxicological side effects of the iteratively produced peptides, cell viability was evaluated by MTS assay. RBE cells were seeded in 96-well plates at 5 × 
Peptide precipitation
RBE cells were lysed in 1 ml of NP-40 buffer (0.25% or 1% Nonidet P-40, 142.5 mM KCl, 5 mM MgCl2, 10 mM HEPES [pH 7.6], 0.2 mM PMSF, 1 mM EDTA) with proteinase inhibitor cocktail Complete Mini (Roche-diagnostics, Basel, Switzerland) [22] .
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The lysate was mechanically dislodged from the plate. The lysate from one dish was incubated on ice, and centrifuged at 15000g for 15 minutes. The supernatant was precipitated with 40 μl of streptavidin-conjugated agarose beads (Invitrogen, Grand
Island, NY) and 20 μl of diluted biotinylated-peptide and incubated for 1 hour at 4°C.
After incubation, the streptavidin-conjugated agarose beads were washed with lysis buffer 4 times and centrifuged for 1 minute, and the supernatant was discarded. The precipitated proteins were subjected to SDS-PAGE, and protein bands were excised from
Coomassie brilliant blue-stained gel. The excised proteins were identified by mass spectrometry (nano LC-ESI-Q-TOF MS/MS) and then searched for in the NCBI nr protein database using their tandem mass spectra and the MASCOT algorithm (Matrix Science). previously [22] .
Immunoprecipitation
Expression plasmids and siRNAs
CHC and GRP78 expression plasmids were cloned into the Hind III site of pcDNA3 (Invitrogen, Grand Island, NY) by polymerase chain reaction (PCR) using primer sets of GCAAGCTTGCCATGGCCCAGATTCTGCCAA and AGAAGCTTCACATGCTGTACCCAAAGCCAG, or into the KpnI and XhoI sites of pcDNA3 by PCR using primer sets of ATGGTACCACCATGAAGCTCTCCCTGGTGG and ATCTCGAGCTACAACTCATCTTTTTCTGCT from human expressed sequence tag (EST) clones (Clone id: 6045540 and 10004803, respectively) purchased from Openbiosystems (Huntsville, AL, USA). The plasmids were sequenced to ensure that the correct sequences were inserted. CHC-and GRP78-specific Trilencer-27 siRNA kits were purchased from OriGene Technologies (Rockville, MD, USA).
Transfection of expression plasmids or siRNAs
1×10
4 RBE cells/100 μl well were transfected with 0.34 μg of CHC and/or GRP78 expression plasmids or empty plasmid alone (negative control) by Lipofectamine 2000 (Invitrogen, Grand Island, NY) in accordance with the manufacturer's instructions.
Immunohistochemistry Immunohistochemistry was performed as described previously [11] . Anti-CHC rabbit polyclonal antibody (ab24578; Abcam, Cambridge, UK) or anti-GRP78 rabbit polyclonal antibody (ab21685; Abcam, Cambridge, UK) was diluted 1:100 in blocking buffer and exposed to the tissues overnight at 4°C.
Evaluation of immunoreactivity of CHC and GRP78
For the protein expression in human sections, evaluation of immunoreactivity of anti-CHC and anti-GRP78 antibodies was as follows: 3(+) is defined as strong complete submembranous and uniform intense intracellular staining, 2(+) is defined as weak complete submembranous staining or uniform intense intracellular staining, 1(+) is defined as weak, incomplete submembranous or partial intracellular staining in any proportion of tumor cells, and 0 is defined as there being no specific staining.
Statistics
Results are presented as the mean and standard deviation. Levels of significance were evaluated using Student's t test. A p-value <0.05 was considered statistically significant. Correlation was measured using Pearson's product-moment correlation coefficient.
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RESULTS
Identification of peptide motifs binding to human cholangiocarcinoma RBE cells
In vitro biopanning was performed as described previously with slight affinity was evaluated by cell-based ELISA (Fig. 1A) . We selected a single phage clone, #35, expressing the sequence "TPVLETPKLLLW", which exhibited higher affinity to RBE cells than the other clones at the concentrations tested (Fig. 1A, #35 ). We defined the peptide as CCA-binding oligo-peptide #35 (COP35).
Binding of COP35 to human CCA cell lines
To evaluate the affinity and specificity of COP35 to several cancer cell lines, binding assays were performed in a variety of cell lines including ICC cell lines RBE, IHGGK, and HuH-28, the ECC cell line TFK-1, the hepatocellular carcinoma cell line Hep3B, and the normal cholangiocyte cell line MMNK-1. COP35 demonstrated significantly higher affinity to cancerous cell lines, RBE, HuH-28, TFK-1, IHGGK, and Hep3B, than to normal cholangiocyte cell line MMNK-1 (Fig. 1B) .
Fluorescence microscopy analysis of COP35 binding to RBE cells
To confirm the binding and specificity of COP35 to CCA cell lines, we utilized NHS-fluorescein-labeled COP35 for fluorescence microscopy. Fig. 2A, lower left panel) . Furthermore, no significant fluorescence was observed in RBE or MMNK-1 cells when a control peptide "HAKSPEMCTFVG", which retains the overall net hydrophobic/hydrophilic and charge properties, was used as a negative control (Fig. 2A, upper and lower central panels).
Fluorescence was observed in both RBE and MMNK-1 cells incubated with trans-acting activator of transcription (TAT) peptide "GRKKRRQRRRPPQ" as a cell-penetrating positive control peptide ( Fig. 2A , upper and lower right panels) [23] .
Evaluation of COP35 binding to clinically resected CCA samples
To test whether COP35 retained its capacity to bind to cells from samples from primary isolated CCA samples, eighteen CCA cases and nontumorous liver and biliary tissues of the same samples were stained with the NHS-fluorescein-labeled COP35 peptide. The median age of the patients was 64.7 y/o (range: 34 to 77 years old), and 10 patients were male and 8 patients were female. The tumor histology is presented in Table   1 . Representative figures are shown (Fig. 2B) . Fluorescence was observed in the CCA samples including both ICC ( hematoxylin and eosin staining images are presented (Fig. 2B, bottom panels) .
Enhancement of the tumor inhibitory effect of 5-fluorouracil by COP35 against RBE cells
To evaluate whether COP35 could enhance the anti-tumor activity of 5-fluorouracil (5-FU) on RBE cells, tumor inhibitory effect was quantified in the presence of COP35 or control peptide (Fig. 2C) . We next evaluated the effect on cell growth of 5-FU against RBE cells in the presence of COP35 or the control peptide by MTS assay (Fig. 2D ). COP35 and 5-FU were added together and cell viability quantified after 36 or 48 hours of incubation. COP35 significantly enhanced the tumor inhibitory effect of 10 μg/ml 5-FU against RBE cells when it was incubated with 500 μM COP35 following both 36 and 48 hours of incubation (Fig. 2D) . The COP35 peptide alone demonstrated no tumor inhibitory effect (Fig. 4A) .
Identification of the COP35 binding partners
To identify putative binding partners for COP35, RBE cells were lysed with detergent concentrations of 0.25% or 1% NP-40 buffer and precipitated using biotinylated COP35 with streptavidin-conjugated agarose beads (Fig. 3A, left panel) . As shown in the left panel of Figure 3A , a sharp band was found at approximately 190-kDa regardless of which buffer was used (Fig. 3A, 
we decreased the concentration of COP35 in 0.25% NP-40 buffer, while we found only an approximately 190-kDa band precipitated with 20 μmol COP35 in lysis buffer (Fig. 3A, central panel, arrowhead with band Q), another band was found to appear around 80-kDa precipitated with 4.0-2.0 μmol COP35 in lysis buffer (Fig. 3A, central panel, arrowhead with band R). The band disappeared at concentrations below 0.2 μmol COP35 in lysis buffer (Fig. 3A, central panel, arrowhead with band R) . We applied liquid chromatography-mass spectrometry (nano LC-ESI-Q-TOF MS/MS) analysis to identify both "Q" and "R" bands. A search for its tandem mass spectra in the NCBI nr protein database using MASCOT identified these two bands, "Q" as the clathrin heavy chain (CHC) with ion score 75 (Fig. 3A, upper right panel) , and "R" as GRP78/BiP with ion score 120 (Fig. 3A, lower right panel) . For further confirmation, RBE cell lysate was precipitated with COP35 or the control peptide (Fig. 3B) . The precipitated proteins were subjected to SDS-PAGE (Fig. 3B, left panel) following immunoblotting analysis with detection using anti-CHC monoclonal antibody (Fig. 3B , central panel, arrowhead with CHC) and anti-GRP78 monoclonal antibody (Fig. 3B , right panel, arrowhead with GRP78). A band of molecular weight ~ 190-kDa was recognized by an anti-CHC monoclonal antibody (Fig. 3B, central panel, arrowhead with CHC) . The CHC band disappeared with a decrease of COP35 titration, whereas no signal was detected in the control peptide precipitation. In addition to the CHC band, a band of around 80-kDa recognized by anti-GRP78 monoclonal antibody appeared (Fig. 3B, 
SDS-PAGE data (Fig. 3A , central panel, arrowhead with band R). Next, we confirmed the interaction between CHC and GRP78 by immunoprecipitation (Fig. 3C ) and dual immunofluorescence staining of CHC and GRP78 in RBE cells (Fig. 3D) . Endogenous GRP78 was found to be co-precipitated with anti-CHC monoclonal antibody (Fig. 3C, α   CHC) . As controls, the precipitate with anti-GRP78 polyclonal antibody was also detected by anti-GRP78 monoclonal antibody, whereas the precipitate with anti-Myc polyclonal antibody or anti-Flag monoclonal antibody was not detected by anti-GRP78 monoclonal antibody (Fig. 3C) . In dual immunofluorescence microscopy, GRP78 clearly co-localized with CHC (Fig. 3D, arrowheads) . The green CHC signals were partially merged with GRP78 signals, and both appeared to be located in perinuclear cytoplasm and cellular periphery in RBE cells (Fig. 3D , Merge and Merge (high power), arrowheads). In human resected tumors, we performed triple immunohistochemical staining for tissues from CCA patients using NHS-fluorescein-labeled COP35 (green), anti-CHC mouse monoclonal antibody with Alexa-Fluor TM 647-conjugated secondary antibody (blue), and anti-GRP78 rabbit polyclonal antibody with TMR-conjugated secondary antibody (red). We found substantial colocalization between the COP35 and CHC fluorescence signals (blue-green) (Fig. 3E, lower central panel, arrowheads) . We also noticed some partial colocalization between COP35 and GRP78 (yellow) (Fig. 3E, upper right panel, arrowheads) and these three fluorescence signals were merged at the cellular periphery (green-yellow) (Fig. 3E , lower right panel, arrowheads). To examine whether clathrin-mediated endocytosis is required for COP35-mediated cellular binding and internalization, experiments were performed in cells depleted of clathrin through treatment with chlorpromazine. RBE cells were incubated with 100 μM NHS-fluorescein-labeled COP35 (Fig. 3F, upper panels,   COP35 ) or a control peptide (Fig. 3F , lower panels, Control) with or without 5 μg/ml chlorpromazine hydrochloride for 2 hours. As expected, we observed strong intercellular COP35 fluorescence in RBE cells incubated with vehicle saline alone ( (Fig. 3F, lower panels) .
Effect of cellular clathrin depletion on COP35 binding and internalization
Effect of overexpression, siRNA-mediated silencing of CHC and/or GRP78, or clathrin depletion on 5-FU-mediated tumor inhibition in combination with COP35
To examine whether the enhancement of the 5-FU-mediated tumor inhibitory effect by COP35 depends on CHC and/or GRP78, we evaluated the tumor inhibitory effect of 5-FU with overexpression or siRNA-mediated knockdown of the COP35 binding partners CHC and/or GRP78 in RBE cells (Fig. 4A and B) . Furthermore, we evaluated the tumor inhibitory effect of 5-FU in the presence or absence of chlorpromazine (Fig. 4C) . We found that the significant difference in tumor inhibitory 5-FU was enhanced by overexpression of CHC and/or GRP78 (Fig. 4A) . Overexpression of CHC and/or GRP78 in transfected RBE cells was confirmed by Western blotting (Fig.   4A, insets) . Furthermore, we found a loss of effect of COP35 in enhancing the tumor inhibitory effect of 5-FU following the specific knockdown of CHC and/or GRP78 using siRNAs (Fig. 4B) . Reduced expression of CHC and/or GRP78 was confirmed by Western blotting (Fig. 4B, insets) . Furthermore, we found that the significant difference in tumor inhibitory effects observed between COP35 and control peptide in RBE cells incubated with 5-FU was abolished when RBE cells were incubated with 5 μg/ml chlorpromazine hydrochloride to deplete clathrin (Fig. 4C) .
Evaluating the expression of CHC and GRP78 in CCA specimens
We confirmed expression of both CHC and GRP78 by immunohistochemistry in formalin-fixed paraffin-embedded human CCA specimens (Fig. 5A) . We evaluated the immunoreactivity of anti-CHC and anti-GRP78 antibodies in eighteen cases (the same patient group as for when we evaluated COP35 binding to clinically resected CCA samples (Table 1) ). Representative figures are shown (Fig. 5A) . Evaluations of the immunoreactivity of CHC and GRP78 are presented in Table 1 , and plotted in Figures 5B and C. Expression of CHC and GRP78 was found to be higher in ICC (Fig. 5A, ICC immunoreactivities of CHC and GRP78 in tumor and nontumorous tissues, which were plotted ( Fig. 5B and C) . We found that the arithmetic mean (M) immunoreactivities of CHC (M=2.4) and GRP78 (M=1.3) in tumor tissues were significantly higher than those of CHC (M=1.1) and GRP78 (M=0.062) in nontumorous tissues with paired t-test probabilities **p<0.01 (Fig. 5B and C) .
Correlation between COP35 fluorescence intensity and immunoreactivity of CHC and GRP78
Since COP35 bound to both CHC and GRP78, we examined whether COP35 fluorescence intensity positively correlated with the immunoreactivity of CHC and GRP78 in the same patient samples presented in Table 1 . We found that COP35 fluorescence intensity was statistically correlated with the immunoreactivity of CHC and GRP78 with Pearson's product-moment correlation coefficient R=0.706 with p-value=0.00154, and R=0.531 with p-value=0.0282, respectively ( Fig. 5D and E) .
DISCUSSION
CCA is known to have a poor prognosis carcinoma compared to many other malignant tumors [1] [2] [3] [4] . Novel therapeutics are urgently required to effectively treat CCA.
Peptide-presenting phage display libraries are powerful tools for iteratively producing ligands that can bind to specific targets [9] [10] [11] [12] . In this study, we utilized a phage display library to identify a novel peptide, defined as COP35. COP35 selectively bound to CCA derived from clinically resected specimens from patients as well as CCA cell lines (Fig. 1,   2A and B) . Therefore, we consider that COP35 binds to a CCA-specific target ligand. In addition, COP35 was found to enhance the tumor inhibitory effect of 5-FU (Fig. 2C and   D ).
Using liquid chromatography-mass spectrometry (nano LC-ESI-Q-TOF MS/MS), we identified the clathrin heavy chain (CHC) as a COP35 binding partner (Fig.   3A) . The molecular weight of CHC is 192-kDa, which is consistent with our SDS-PAGE results and following immunoblotting detected with anti-CHC monoclonal antibody ( Fig.   3A and B) . Clathrin is the major protein component of a major class of coated vesicles, and plays an important role in endocytosis [24] [25] [26] , a pathway known to be involved in pathogen internalization [27, 28] . We therefore speculated that COP35 is internalized via a clathrin-dependent endocytic pathway by direct or indirect interaction with CHC in living cells. Using TAT peptide as a cell-penetrating positive control peptide for peptide internalization, fluorescence was detected ubiquitously in all cells, while fluorescence signal from COP35 was specifically detected in RBE cells and not MMNK-1 cells (Fig.   2A) . Thus, it is suggested that the internalization of COP35 in RBE cells may occur in a different way from that for cell-penetrating peptide. Since it was reported that endocytosis might be accelerated in CCA cells because of their motility and high-energy demand [29] , we examined the effect of an inhibitor of clathrin-mediated endocytosis, chlorpromazine, to investigate whether COP35 is actually internalized into CCA cells via clathrin-mediated endocytosis. We found that depletion of clathrin using chlorpromazine 
inhibited the COP35 internalization in RBE cells (Fig. 3F) . The result supports our hypothesis that COP35 is internalized via clathrin-mediated endocytosis. It was also suggested that CHC is up-regulated in hepatocellular carcinoma tissues [30] . Consistent with this, our data suggest that CHC expression in CCA lesions was higher than that in normal bile duct epithelium by immunohistochemical staining of formalin-fixed and paraffin-embedded tissues (Table 1) (Fig. 5A, upper panels, and B) . Thus, it was suggested that CHC could be an attractive target of COP35.
Notably, as we decreased the concentration of COP35, another clear band became apparent around 80-kDa precipitated with CHC (Fig. 3A, central panel, arrowhead with band R). The 80-kDa protein was determined to be a glucose-regulated protein of 78-kDa (GRP78, also referred to as BiP) (Fig. 3A, right panel, band R) . GRP78 is a member of the heat shock protein 70 family that functions as a chaperone critical for folding, maturation, and transport of polypeptides and proteins, which is expressed on the cell surface where it functions as a receptor for a wide variety of ligands [31, 32] . GRP78 is also important in the unfolded protein response that ameliorates stress conditions, such as glucose starvation and hypoxia, which are characteristic of malignant tumors, and serves to protect tumor cells against cell death [33, 34] . GRP78 has been reported to be strongly expressed in gastric and prostate cancer, and correlate with their aggressive behavior and poor prognosis [35, 36] . The induction of GRP78 by unfolded protein response during endoplasmic reticulum stress is reported to be required for pathophysiologic conditions, such as tumor proliferation, survival, and angiogenesis [37] .
Consistent with this, our findings indicated that GRP78 was highly expressed in CCA (Table 1) (Fig. 5A, middle panels, and C) . The interaction between CHC and GRP78 is likely to affect the tumor inhibitory effect of 5-FU. We found that COP35 enhanced the tumor inhibitory effect of 5-FU (Fig. 2C and D) , and siRNA-mediated knockdown of CHC and/or GRP78 and chlorpromazine treatment of RBE cells resulted in abolishment of the enhancement of the 5-FU tumor inhibitory effect of COP35 (Fig. 4B and C) , while overexpression of CHC and/or GRP78 in RBE cells resulted in an enhanced 5-FU mediated tumor inhibitory effect of COP35 (Fig. 4A ). In addition, the ability of COP35 to bind to clinical samples was statistically correlated with the expression of CHC and GRP78 ( Fig. 5D and E) . Thus, it was suggested that both CHC and GRP78 are important molecules for the function of COP35 in enhancing the tumor inhibitory effect of 5-FU.
As shown in Figure 3 , while high concentration (20.0 μmol) of COP35 bound only to CHC, the lower concentration (4.0-2.0 μmol) of COP35 bound to CHC accompanied by GRP78 (Fig. 3A, central panel, and B) . We speculate that COP35 could directly bind to CHC, which may interact with a surface receptor protein GRP78. The hypothesis was also confirmed by further evidence that GRP78 was co-precipitated with CHC by immunoprecipitation, and appeared to co-localize with CHC by immunofluorescence microscopy (Fig. 3C, D and E) . However, we noted the limitation of our study to explain this finding that COP35 interacts with CHC at high concentration and GRP78 at lower concentration, which may reflect a key function of COP35 on enhancement of the tumor inhibitory effect of 5-FU. We speculated that higher concentration of COP35 might induce a conformational change in CHC that reduces the power of binding between CHC and GRP78 under our experimental conditions. Additional studies will be required in order to fully elucidate the mechanism by which COP35 enhances the tumor inhibitory effect of 5-FU prior to clinical studies. It has been reported that a number of prognostic and predictive gene mutations such as k-ras, p53, and Raf/Mek/Erk in tumor can correlate with sensitivity and/or resistance to chemotherapies [38] . In patients, germline pharmacogenetic mutations or polymorphisms can influence chemotherapeutic toxicity [38] . We speculate that metabolism and degradation by nonspecific peptidases and proteases, or clathrin-dependent endocytosis of macrophages, may be different for each patient. Here, we present data suggesting that tumor expression levels of CHC and GRP78 could be important factors for gauging the likely efficacy of 5-FU in combination therapies of COP35 and 5-FU.
IN MEMORIAM
Our colleague, a surgeon, Dr. Fukuto Maruta, died prior to publication of this study. This paper is dedicated to his memory. Representative ICC (Case 1 in Table 1 ), ECC (Case 16 in Table 1 ), and nontumorous normal bile duct epithelium of CCA (Case 1 in Table 1 I  wel  2+  3+  1+  2+  1+  10  55  F  I  wel  2+  3+  1+  1+  0  11  67  F  I  wel  2+  2+  1+  1+  0  12  60  F  I  wel-mod  1+  1+  1+  0  0   13  68  M  I  mod-por  0  0  0  0  0  14  68  F  E  pap  3+  3+  1+  0  0  15  76  M  E  tub  3+  2+  1+  0  0  16  34  M  E  tub  3+  2+  1+  2+  0   17  72  F  E  tub  2+  2+  1+  -*  -18 71 M E pap-tub 2+ 2+ 1+ --Footnote: Age(y/o): age (years old) at surgery. Gender, female (F) and male (M); Location, intrahepatic (I), extrahepatic (E); Histology, well-differentiated adenocarcinoma (wel), moderately differentiated adenocarcinoma (mod) and poorly differentiated adenocarcinoma (por) in intrahepatic cholangiocarcinoma, and tubular adenocarcinoma (tub) or papillary adenocarcinoma (pap) in carcinoma of the extrahepatic bile ducts, tumorous tissue (T), nontumorous tissue (NT). *There is no nontumorous tissue. 
